Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Colon Cancer

Aliases
Colon Carcinoma, Recurrent Colon Carcinoma

141 clinical trials

161 products

33 drugs

Clinical trial
A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2024-12-30
Product
COM902
Product
COM902 in combination with COM701
Product
MDX2001
Clinical trial
A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2028-08-01
Product
COM902 + COM701
Product
E-602
Product
CEA-targeted CAR-T cells
Clinical trial
Chimeric Antigen Receptor T Lymphocytes (CAR-T) Targeting CEA in the Treatment of CEA Positive Clinical Study of Advanced Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and Non-MSI-H Colon Cancer
Status: Active (not recruiting), Estimated PCD: 2024-02-16
Product
Ipilimumab
Product
Nivolumab
Product
Cobimetinib
Product
Daratumumab
Product
BMS-986016
Clinical trial
A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Cancers
Status: Recruiting, Estimated PCD: 2025-06-01
Product
COM902 + COM701 + Pembrolizumab
Product
Erlotinib
Product
Docetaxel
Product
Cemiplimab
Product
AZD6244
Clinical trial
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) When Given in Combination With Standard Doses of Selected Chemotherapies to Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2010-08-20
Product
LOXO-292
Clinical trial
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Status: Recruiting, Estimated PCD: 2025-02-28
Product
Dacarbazine
Product
Temsirolimus
Product
Triplet combination of COM902 + COM701 + Pembrolizumab
Product
Labetuzumab Govitecan
Clinical trial
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer
Status: Terminated, Estimated PCD: 2017-01-03
Clinical trial
An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Product
BI 754091
Product
VSV-GP128
Product
ATP128
Clinical trial
A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B694, an Autologous Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Status: Recruiting, Estimated PCD: 2028-06-01
Product
A2B694
Clinical trial
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-06-01
Product
SNS-101
Clinical trial
A Phase I, Open Label, Dose-Escalation, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR106 in Patients With Select Relapsed Advanced Malignancies (JIVAN)
Status: Recruiting, Estimated PCD: 2025-05-01
Product
AUR106
Product
Ompenaclid
Clinical trial
A Randomized Phase 2 Study of Ompenaclid Versus Placebo in Combination With FOLFIRI Plus Bevacizumab in Patients With Previously Treated RAS Mutant Advanced or Metastatic Colorectal Cancer
Status: Recruiting, Estimated PCD: 2026-08-01
Product
Bevacizumab
Product
Placebo
Product
FOLFIRI
Product
ART-123
Clinical trial
Phase 2 Clinical Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer: a Multicenter Randomized Placebo-controlled Double-blind Study to Investigate the Efficacy and Safety of ART-123
Status: Completed, Estimated PCD: 2018-02-01
Clinical trial
A Phase 2 Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer Who Have Received Two or Three Prior Systemic Chemotherapy Regimens
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
CTX-009
Product
COM902 (RDFE)
Product
HBI-2438
Clinical trial
A Phase 1, Open Label, Dose Escalation of HBI-2438 in Patients With Advanced Malignant Solid Tumors Harboring KRAS G12C Mutation
Status: Recruiting, Estimated PCD: 2025-08-01
Product
Panitumumab
Clinical trial
A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer
Status: Completed, Estimated PCD: 2012-05-30
Clinical trial
A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma Not Amenable to Resection or Transplant
Status: Active (not recruiting), Estimated PCD: 2022-12-01
Product
mFOLFOX6
Product
PV-10
Clinical trial
A Phase 1-2 Dose-escalation and Expansion Study of ST316 in Subjects With Selected Advanced Unresectable and Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-05-31
Clinical trial
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Status:
Product
Selpercatinib
Product
Cyclophosphamide
Clinical trial
A Phase I/II Trial in Patients With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System
Status: Recruiting, Estimated PCD: 2023-09-01
Product
Fludarabine
Product
Tumor-Infiltrating Lymphocytes
Product
Aldesleukin
Product
ST316
Product
Foxy-5
Clinical trial
A Randomized, Multicentre, Open-Label Controlled Phase II Trial of Foxy-5 as Neo-Adjuvant Therapy in Subjects With Wnt-5a Low Colon Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-14
Product
²¹²Pb-DOTAM-GRPR1
Product
Fruquintinib
Clinical trial
Consequences of Co-Administration of Propofol With Clonidine and Ketamine Throughout Colon Cancer Surgery
Status: Completed, Estimated PCD: 2022-01-01
Clinical trial
A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2022-12-13
Clinical trial
A Phase 1 Open-Label Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, and Preliminary Efficacy of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-03-30
Product
XLJDOD
Clinical trial
Efficacy of Xian-Lian-Jie-Du Optimization Decoction as an Adjuvant Treatment for Prevention of Recurrence of Stage IIIB/IIIC Colon Cancer：a Study Protocol for a Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2024-12-01
Product
TCI Propofol
Clinical trial
Chimeric Antigen Receptor T Lymphocytes (CAR-T) Targeting CEA in the Treatment of CEA Positive Clinical Study of Advanced Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-31
Product
FOLFOX
Product
APL-101
Product
MRTX849
Product
BI 1701963
Clinical trial
A Phase 1/1b Trial of MRTX849 in Combination With BI 1701963 in Patients With Advanced Solid Tumors With KRAS G12C Mutation
Status: Completed, Estimated PCD: 2022-11-02
Clinical trial
A Phase Ib Trial of Neoadjuvant PalloV-CC (Particle-delivered, Allogeneic Tumor Cell Lysate Vaccine for Colon Cancer) in Colon Cancer
Status: Completed, Estimated PCD: 2023-04-19
Product
RSC-1255
Product
PalloV-CC
Clinical trial
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2022-07-29
Clinical trial
A Phase Ia/Ib, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of RSC-1255 in Patients With Advanced Solid Tumor Malignancies
Status: Recruiting, Estimated PCD: 2024-01-16
Clinical trial
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. A Multicenter Phase 1b/2a Trial in Colorectal Cancer, Non-small Cell Lung Cancer, and Soft Tissue Sarcoma Patients
Status: Recruiting, Estimated PCD: 2024-05-01
Product
IP-001
Product
CEA CAR-T cells
Clinical trial
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
Status: Terminated, Estimated PCD: 2015-06-22
Product
E7820
Clinical trial
A Safety and Efficacy Clinical Study of CEA-targeted CAR-T Therapy forCEA-positive Advanced/Metastatic Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
Status: Recruiting, Estimated PCD: 2029-10-01
Product
Systemic Treatment
Clinical trial
Phase II Study of Isolated Hepatic Perfusion With Melphalan Followed By Postoperative Hepatic Arterial Chemotherapy in Patients With Unresectable Colorectal Cancer Metastatic to the Liver
Status: Completed
Product
floxuridine
Product
Leucovorin
Product
melphalan
Clinical trial
Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
Status: Withdrawn, Estimated PCD: 2024-02-09
Drug
Regorafenib
Product
XmAb20717
Clinical trial
Phase II Single-arm Study of the Combination of Palbociclib and Cetuximab in KRAS/NRAS/BRAF Wild-type Metastatic Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2023-05-29
Product
Cetuximab
Product
Palbociclib
Clinical trial
3T: A Phase II Single Arm Open Label Study of Tucatinib Combined With Trastuzumab and TAS-102 in Molecularly Selected Patients With HER2+ Metastatic Colorectal Cancer
Status: Not yet recruiting, Estimated PCD: 2024-05-30
Drug
Trastuzumab
Product
Trifluridine and Tipiracil
Drug
Tucatinib
Clinical trial
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Product
PCR/PCR/LDR Strategy
Clinical trial
A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer
Status: Recruiting, Estimated PCD: 2025-09-30
Product
LY2880070
Drug
Gemcitabine
Clinical trial
Pilot Study: Detection of Carcinomas Using 64Cu-Labeled M5A Antibody to Carcinoembryonic Antigen (CEA)
Status: Active (not recruiting), Estimated PCD: 2022-03-06
Product
Cu 64 anti-CEA monoclonal antibody M5A
Clinical trial
A Phase III Double-blind Placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2027-12-01
Drug
Aspirin
Clinical trial
A Phase I Clinical Trial of Regorafenib, Nivolumab, and Ipilimumab in Advanced Chemotherapy Resistant Metastatic MSS Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
The Combination of Everolimus and PD-1 in the Treatment of Locally Advanced and Advanced Colorectal Cancer That Cannot be R0 Resected
Status: Not yet recruiting, Estimated PCD: 2026-05-01
Product
Everolimus
Product
PD-1
Product
Acetylsalicylic acid
Clinical trial
Adjuvant Chemotherapy In Elderly With Colon Cancer Stage III - Geriatric Assessment and Prognostic Gene Signatures
Status: Active (not recruiting), Estimated PCD: 2022-11-01
Product
Capecitabine
Clinical trial
Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced But Resecable Colon Cancer in the Elderly of 70 Years Old or More Phase III Multicentric Open-label Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2032-06-01
Product
Folfox
Clinical trial
A Phase I Clinical Trial of Trametinib in Combination With TAS-102 in Patients With Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild-Type) Metastatic Colorectal Cancer
Status: Completed, Estimated PCD: 2023-07-14
Product
Trametinib
Clinical trial
Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (Amended Protocol of: Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL)
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Celecoxib
Product
BMS-986253
Clinical trial
Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
Phase I Study of Regorafenib and Nivolumab in Mismatch Repair (MMR) Proficient Advanced Refractory Colorectal Cancer
Status: Completed, Estimated PCD: 2021-09-01
Drug
mFOLFOXIRI
Clinical trial
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
Status: Active (not recruiting), Estimated PCD: 2024-07-15
Drug
CAPOX
Clinical trial
Determining the Safety and Feasibility of Optical Coherence Tomography and Near Infrared Fluorescence: a Prospective Pilot Intervention Study
Status: Not yet recruiting, Estimated PCD: 2024-09-01
Product
Bevacizumab-800CW
Clinical trial
The Effect of Probiotics ATG-F4 in Cancer Patients
Status: Recruiting, Estimated PCD: 2024-12-31
Product
LT-002
Clinical trial
Phase Ib/II Trial of SX-682 in Combination With Nivolumab for Refractory RAS Mutated (RAS) Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) (STOPTRAFFIC-1)
Status: Recruiting, Estimated PCD: 2025-01-31
Product
SX-682
Clinical trial
Phase II, Single Arm Study of Neoadjuvant Dostarlimab (TSR-042) in Stage II and III Deficient Mismatch Repair Colon Cancers
Status: Recruiting, Estimated PCD: 2026-04-01
Product
Dostarlimab
Clinical trial
Phase I Randomized Study of MAGE-12 Peptide Vaccine in Patients With Refractory Metastatic Cancer Expressing MAGE-12 Antigen
Status:
Drug
interleukin-2
Product
MAGE-12
Product
Montanide ISA-51
Clinical trial
Efficacy of Immunotherapy in Patients With MMR-deficient Localized Colon Cancer Scheduled for Curative Surgery - A Prospective, Phase II Study
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Product
Pembrolizumab
Clinical trial
Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial
Status: Active (not recruiting), Estimated PCD: 2023-09-14
Clinical trial
Phase II Multicenter Trial of Panitumumab, Nivolumab, and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2020-09-21
Clinical trial
Novel Dynamic PET Kinetics and MRI Radiomics Analyses in Brain Tumors
Status: Completed, Estimated PCD: 2023-09-18
Product
18F-FMAU
Clinical trial
Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial
Status: Completed, Estimated PCD: 2022-05-31
Product
Trifluridine Tipiracil
Clinical trial
A Prospective, Single-center, Multi-cohort Study of Envolimab Monotherapy or Envafolimab in Combination With CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer.
Status: Recruiting, Estimated PCD: 2024-07-01
Drug
Envafolimab
Product
CAPEOX
Clinical trial
Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections
Status: Withdrawn, Estimated PCD: 2022-11-30
Product
Cook Medical EMR
Clinical trial
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
Status: Active (not recruiting), Estimated PCD: 2022-11-01
Clinical trial
Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Drug
AN0025
Product
Olaparib
Product
Cediranib
Clinical trial
An Open Label Randomised Trial to Assess the Efficacy of Post-Operative Ferric Maltol Vs Standard Care for Anaemia Following Colorectal Cancer Surgery
Status: Recruiting, Estimated PCD: 2025-05-29
Product
Oral Ferric Maltol
Clinical trial
Sequential Combined TAS-102 and Oxaliplatin Alternating With TAS-102 and Irinotecan (Sequential TASOXIRI) With Bevacizumab for Late-Line Metastatic Colorectal Cancer
Status: Recruiting, Estimated PCD: 2026-05-01
Product
TAS-102
Product
Irinotecan
Clinical trial
TAS-102 in Combination With Oxaliplatin (TAS-OX) for Refractory Metastatic Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2024-03-31
Drug
mFOLFOX6
Clinical trial
Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer
Status: Active (not recruiting), Estimated PCD: 2023-06-01
Drug
UTD1
Clinical trial
Pharmacodynamic Effects of Fatty Acid Synthase (FASN) Inhibition With TVB-2640 in Resectable Colon Cancer and Other Resectable Cancers; a Window Trial.
Status: Recruiting, Estimated PCD: 2024-12-31
Product
TVB-2640
Clinical trial
Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy : A Randomized Phase III Trial - COnCERTO (French 01-18)
Status: Not yet recruiting, Estimated PCD: 2031-01-01
Product
Neoadjuvant chemotherapy
Clinical trial
Randomized Phase II Trial of Encorafenib and Cetuximab With or Without Nivolumab (NSC #748726) for Patients With Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Status: Recruiting, Estimated PCD: 2024-08-31
Product
Encorafenib
Clinical trial
An Open, Single-arm, Multicenter, Prospective Phase II Study of Fuquinitinib Combined With Tegafur Gimeracil Oteracil in the Third-line Treatment of Patients With Advanced Metastatic CRC
Status: Not yet recruiting, Estimated PCD: 2027-03-21
Product
Fuquinitinib + Tegafur Gimeracil Oteracil
Clinical trial
A Randomized Trial of Microbiotic Product (NBT-NM108) to Promote Microbiome Health and Improve Chemotherapy Delivery
Status: Recruiting, Estimated PCD: 2025-07-01
Product
NBT-NM108
Clinical trial
Preoperative i.v. Iron Substitution in Patients With Colon Carcinoma and Iron-deficiency Anemia
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Ferric Carboxymaltose
Product
Pertuzumab
Clinical trial
Preoperative Endoscopic Treatment With Fosfomycin and Metronidazole in Patients With Right-sided Colon Cancer and Colon Adenoma: a Clinical Proof-of-concept Intervention Study MEFO Trial
Status: Completed, Estimated PCD: 2022-04-13
Product
Therapeutic Endoscopy with Metronidazole and Fosfomycin Disodium
Clinical trial
A Phase III Double-blind Placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2027-12-31
Drug
acetylsalicylic acid
Drug
Varlilumab
Clinical trial
Efficacy of Neoadjuvant Immunotherapy for T4 Deficient Mismatch Repair (dMMR) Colon Cancer: A Prospective, Single-arm, Phase Ⅱ Clinical Trial
Status: Recruiting, Estimated PCD: 2025-02-10
Product
Camrelizumab
Clinical trial
Evaluation of Metastatic Disease and Oncological Treatment in Patients With Colon Cancer
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Chemotherapy
Clinical trial
Randomized Ph II Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With IV Systemic Chemo With/Without Bevacizumab (mAB to Vascular Endothelial Growth Factor-A) in Patients With Resected Hepatic Metastases From Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Product
Bevacizumab HAI plus systemic chemotherapy
Product
HAI plus systemic chemotherapy
Clinical trial
Immunotherapy Combined With Yttrium-90 RadioEmbolization in the Treatment of Colorectal Cancer With Liver Metastases [iRE-C - Clinical Trial]
Status: , Estimated PCD: 2023-12-31
Clinical trial
Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer
Status: Recruiting, Estimated PCD: 2026-12-01
Product
FOLFIRI Protocol
Product
Encorafenib + Binimetinib + Cetuximab
Product
Trastuzumab + Pertuzumab
Clinical trial
A Phase II Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2025-02-09
Product
Cabozantinib
Drug
T-VEC
Clinical trial
A Phase Ib Adaptive Study Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Status: Active (not recruiting), Estimated PCD: 2023-06-22
Drug
Atezolizumab
Clinical trial
Laparoscopic vs Ultrasound-Guided Transversus Abdominis Plane Block in Minimally Invasive Colon Surgery: A Randomized Controlled Multicentre Clinical Trial
Status: Recruiting, Estimated PCD: 2024-08-31
Product
Active drug
Product
Dasatinib
Drug
5-FU
Drug
FOLFOXIRI
Clinical trial
A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer
Status: Terminated, Estimated PCD: 2021-07-31
Product
Savolitinib
Clinical trial
A Randomised Placebo-controlled Phase III Trial of the Effect of the Omega-3 Fatty Acid Eicosapentaenoic Acid (EPA) on Colorectal Cancer Recurrence and Survival After Surgery for Resectable Liver Metastases
Status: Active (not recruiting), Estimated PCD: 2025-11-30
Product
Icosapent Ethyl
Clinical trial
A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy
Status: Not yet recruiting, Estimated PCD: 2025-10-31
Drug
cannabidiol
Clinical trial
A Phase III, Randomised, International Trial Comparing mFOLFIRINOX Triplet Chemotherapy to mFOLFOX for High-risk Stage III Colon Cancer in Adjuvant Setting
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
Folfox Protocol
Clinical trial
Preoperative Chemosensitivity Testing as Predictor of Treatment Benefit in Adjuvant Stage III Colon Cancer: PePiTA Trial
Status: Completed, Estimated PCD: 2022-12-01
Clinical trial
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Recruiting, Estimated PCD: 2027-12-01
Drug
cyclophosphamide
Drug
fludarabine
Product
Delta-8-Tetrahydrocannabinol
Clinical trial
Phase IV Multicentric Clinical Trial to Evaluate the Efficacy of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Mytomicin-C After Complete Surgical Cytoreduction in Patients With Colon Cancer Peritoneal Metastases
Status: Recruiting, Estimated PCD: 2027-01-01
Product
complete cytoreductive surgery plus HIPEC with Mytomicin C
Clinical trial
Phase II Open-Label Trial of Neoadjuvant Atezolizumab in Combination With CAPEOX for Resectable Non-Metastatic Proficient Mismatch Repair (PMMR) Colon Cancer
Status: Not yet recruiting, Estimated PCD: 2026-09-01
Product
Tecentriq
Product
Oxaliplatin + Leucovorin + 5-Fluorouracil
Product
Oxaliplatin + Capecitabine
Product
anti-KRAS G12D mTCR PBL
Clinical trial
Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression
Status: Recruiting, Estimated PCD: 2025-08-01
Product
Pegasys
Clinical trial
A Phase I/II Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2022-06-14
Product
Copanlisib
Clinical trial
Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer
Status: Not yet recruiting, Estimated PCD: 2026-02-28
Product
Serplulimab
Clinical trial
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Recruiting, Estimated PCD: 2027-06-29
Product
Anti-KRAS G12V mTCR PBL
Clinical trial
PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer，Single Arm, Multicenter Phase II Clinical Study
Status: Not yet recruiting, Estimated PCD: 2026-01-31
Clinical trial
Doublet or Triplet Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF Wild Type Unresectable Liver Metastasis Right-sided Colon Cancer With Curative Intent：Multi-center, Ambispective Observational Trial
Status: Recruiting, Estimated PCD: 2024-12-30
Product
Doublet or triplet chemotherapy
Clinical trial
Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Metastatic Colorectal Cancer
Status: Not yet recruiting, Estimated PCD: 2027-07-01
Product
Tretinoin
Clinical trial
PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy After Progression on Anti-EGFR Therapy in Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers
Status: Active (not recruiting), Estimated PCD: 2024-09-30
Drug
fluorouracil
Clinical trial
Molecular Analysis for Therapy Choice (MATCH)
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Drug
Adavosertib
Product
Afatinib
Clinical trial
Camrelizumab and Apatinib Combined With Chemotherapy (mFOLFOX6) in Neoadjuvant Therapy for Locally Advanced Colon Cancer
Status: Recruiting, Estimated PCD: 2024-12-30
Product
Binimetinib
Product
Capivasertib
Clinical trial
Genotype-Directed Phase II Study Of Higher Dose Of Irinotecan In First-Line Metastatic Colorectal Cancer Patients Treated With Folfiri Plus Bevacizumab
Status: Active (not recruiting), Estimated PCD: 2027-06-01
Clinical trial
A Pilot Study to Evaluate the Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients With Curative Resections.
Status: Recruiting, Estimated PCD: 2024-09-01
Product
Epigallocatechin gallate
Clinical trial
A Phase I Clinical Trial of Fluorouracil (5-FU) + CPI-613 Combination in Previously Treated Metastatic Colorectal Cancer Patients
Status: Completed, Estimated PCD: 2019-02-19
Product
6,8-bis(benzylthio)octanoic acid
Clinical trial
Phase I/II Study of CB-839 and Capecitabine in Patients With Advanced Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2023-01-01
Product
CB-839
Clinical trial
Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)
Status: Recruiting, Estimated PCD: 2026-03-31
Drug
Ceralasertib
Clinical trial
The Role of Surgery of the Primary Tumour With Few or Absent Symptoms in Patients With Synchronous Unresectable Metastases of Colorectal Cancer, a Randomized Phase III Study. A Study of the Dutch Colorectal Cancer Group (DCCG)
Status: Completed, Estimated PCD: 2022-06-01
Product
Systemic treatment
Product
Trastuzumab Deruxtecan
Clinical trial
Randomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon Cancer
Status: Recruiting, Estimated PCD: 2034-08-01
Drug
cetuximab
Clinical trial
Chronic Intestinal Pathologies Analytical Cohort at TouLouse
Status: Recruiting, Estimated PCD: 2025-09-01
Product
Blood + Intestinal Biopsy Sampling
Clinical trial
Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
Exploratory Clinical Trial on the Safety, Tolerability, Efficacy, and Pharmacokinetics of XKDCT080 in GCC-positive Recurrent or Refractory Solid Tumors With Single Center, Single Arm, and Dose Escalation
Status: Recruiting, Estimated PCD: 2023-12-28
Product
Chimeric antigen receptor T cell GCC
Clinical trial
Value of ctDNA in Surveillance of Chemosensitivity and Regimen Adjustment in Stage III Colon Cancer: a Phase II Randomized Controlled Trial (REVISE Trial)
Status: Recruiting, Estimated PCD: 2025-12-31
Drug
XELOX
Clinical trial
Phase II Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
Status: Completed, Estimated PCD: 2022-05-05
Clinical trial
Single Arm Study of Neoadjuvant Immunotherapy Combined With Chemotherapy in Locally Advanced Colon Cancers
Status: Not yet recruiting, Estimated PCD: 2025-12-31
Product
Terelizumab
Drug
CapeOx
Clinical trial
A Window of Opportunity Study of Pembrolizumab in Colon Cancer
Status: Recruiting, Estimated PCD: 2025-03-19
Clinical trial
Randomized Trial to Compare Propofol to Fentanyl and Midazolam for Colonoscopy.
Status: Completed, Estimated PCD: 2015-03-01
Drug
Ketamine
Product
Propofol
Product
Midazolam
Clinical trial
Study to Identify Transcriptional Targets of Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases Receiving Preoperative Vitamin D Supplementation.
Status: Recruiting, Estimated PCD: 2025-03-31
Drug
Vitamin D3
Clinical trial
Neoadjuvant Chemotherapy for Non-metastatic Locally Advanced Colon Cancer: A Prospective Multicenter Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2026-12-31
Product
Neoadjuvant FOLFOX
Clinical trial
Perioperative Administration of Oral Green Tea Extract/Milk Thistle Extract to Colorectal Cancer Patients Undergoing Colorectal Cancer Resection, a Phase 1 Study
Status: Terminated, Estimated PCD: 2023-02-01
Product
Green Tea and Milk Thistle Supplements
Clinical trial
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
Status: Completed, Estimated PCD: 2022-05-27
Clinical trial
The Effects of Ankaferd Hemostat on Preventing Oral Mucositis in Colorectal Cancer Patients Receiving Chemotherapy
Status: , Estimated PCD: 2023-06-02
Product
Ankaferd Blood Stopper
Clinical trial
Phase II Trial of VEGF Trap in Patients With Previously Treated Metastatic Colorectal Cancer
Status: Completed, Estimated PCD: 2012-09-01
Drug
aflibercept
Product
MVT-5873
Clinical trial
A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2023-06-30
Product
Veliparib
Clinical trial
De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer (DIAMOND Study): A Randomized Phase III of PRODIGE Intergroup
Status: Not yet recruiting, Estimated PCD: 2031-01-01
Product
treatment adaptation guided
Product
Standard Management
Clinical trial
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT-803
Status: Completed, Estimated PCD: 2021-06-01
Product
Natural Killer Cells
Product
ALT803
Clinical trial
A Phase I/II Trial of Pembrolizumab (MK-3475) and Poly-ICLC in Patients With Metastatic Mismatch Repair-proficient (MRP) Colon Cancer
Status: Completed, Estimated PCD: 2022-07-29
Drug
pembrolizumab
Drug
Poly-ICLC
Clinical trial
Dietary Fiber During Radiotherapy and Intestinal Inflammation - a Placebo-controlled Randomized Trial (FIDURA)
Status: Recruiting, Estimated PCD: 2023-12-31
Product
Dietary fiber capsules
Clinical trial
A Phase Ib/II Trial of M7824 in Solid Tumors With Microsatellite Instability With Consensus Molecular Subtype 4 Metastatic Colorectal Cancer in Combination With Radiation, or in Colorectal Cancer Patients With Detectable Circulating Tumor DNA Following Definitive Therapy
Status: Active (not recruiting), Estimated PCD: 2023-08-01
Product
M7824
Clinical trial
DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease
Status: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
Optimization of the Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure
Status: Completed, Estimated PCD: 2023-10-31
Product
Polyethylene glycol
Product
Sodium phosphate
Product
Polyethylene Glycol + Ascorbic Acid
Product
gastrografin
Product
Magnesiumoxid + Sodium Picosulfate
Product
prucalopride
Clinical trial
Treatment of Advanced Colorectal or Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Armed Activated T-Cells (Phase Ib)
Status: Completed, Estimated PCD: 2020-10-19
Drug
FOLFOX6
Product
EGFRBi
Clinical trial
A Randomized Controlled Phase III Trial of Treatment Intensification in Stage II-III Colon Cancer Patients With Positive MRD During Adjuvant Chemotherapy
Status: Recruiting, Estimated PCD: 2028-09-30
Product
mFOLFIRINOX
Product
FOLFOX or CAPOX
Clinical trial
The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
Status: Recruiting, Estimated PCD: 2026-04-30
Clinical trial
Proactive Management of Endoperitoneal Spread in Colonic Cancer
Status: Not yet recruiting, Estimated PCD: 2024-09-01
Product
Standard adjuvant systemic chemotherapy
Clinical trial
First-in-Human, Phase 1b Study of PHN-010, an Antibody Drug Conjugate, in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-04-01
Product
PHN-010
Clinical trial
A Phase II Study of PD-1 Inhibition for the Prevention of Colon Adenomas in Patients With Lynch Syndrome and a History of Partial Colectomy
Status: Terminated, Estimated PCD: 2021-01-25